AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29314344
Drug: Intensive fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive fluoride varnish treatment (three applications within 2 weeks and additional applications at 1 and 3 months)
Trial: 29314344
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (semi-annual fluoride varnish treatment)
Trial: 10102764
Drug: Citicoline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (500 mg bid)
Trial: 7778430
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol for 12 weeks
Trial: 17459479
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of intravitreal triamcinolone (TA)
Trial: 17459479
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of intravitreal triamcinolone (TA) combined with sequential grid laser
Trial: 14717388
Drug: Beta-blockers in
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers in addition to digoxin, diuretics, and ACE inhibitors
Trial: 11115031
Drug: Early home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early home-based intervention with weekly home visits from a child health nurse for 6 weeks, then fortnightly visits to 3 months, with some receiving short-term dynamic therapy from a social worker.
Trial: 9190006
Drug: Floctafenin, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floctafenin, 800 mg/day
Trial: 9190006
Drug: Acetaminophen, 3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, 3000 mg/day
Trial: 1541877
Drug: Warfarin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin as an adjuvant to standard treatment
Trial: 1541877
Drug: Warfarin enantiomers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin enantiomers (R,S) analysis
Trial: 1541877
Drug: Warfarin disposition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin disposition
Trial: 3020703
Drug: Sequential hemibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential hemibody radiotherapy
Trial: 31322496
Drug: Peripheral blood
RxNorm normalized name: Peripheral blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood mononuclear cells (PBMC) transfer; 0.4 ml of cultured PBMCs transferred into the uterus two days prior to embryo transfer
Trial: 31229622
Drug: GEM intervention
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM intervention (tablet-delivered goal setting tool, health coaching visit, twelve telephone calls, provider counseling training)
Trial: 24322191
Drug: Fresh cheese
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh cheese enriched with Bifidobacterium lactis Bi‐07 (30 g/day for 30 days)
Trial: 24322191
Drug: Regular fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular fresh cheese (30 g/day for 30 days)
Trial: 10773903
Drug: Mega-dose capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mega-dose capsule distribution
Trial: 21739240
Drug: Modified-policosanol (MP)
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-policosanol (MP) 20 mg daily with background statin therapy
Trial: 21739240
Drug: Modified-policosanol (MP)
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-policosanol (MP) 20 mg daily as monotherapy
Trial: 21739240
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with background statin therapy
Trial: 17024505
Drug: Ertapenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (1 g daily)
Trial: 17024505
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g every 12 h with optional metronidazole 500 mg every 12 h)
Trial: 15219514
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of autologous bone marrow mesenchymal stem cell
Trial: 11174623
Drug: First-phase insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-phase insulin release during IV-GTT
Trial: 8501503
Drug: VCMP/VBAP combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCMP/VBAP combination chemotherapy
Trial: 30005643
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support intervention with monthly group education on diabetic retinopathy (DR) and individual reminders for eye examination
Trial: 28511614
Drug: NTP-CE (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTP-CE (new topical panthenol-containing emollient)
Trial: 25626962
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (group C)
Trial: 12535822
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/daily
Trial: 12535822
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/daily
Trial: 10825055
Drug: Thalidomide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (400 mg/d for 1 week, then 200 mg/d for 7 weeks)
Trial: 2125605
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg once daily for 1 week
Trial: 2125605
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg once daily for 1 week
Trial: 29460236
Drug: XEN-D0103 50
RxNorm normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN-D0103 50 mg bd
Trial: 1951080
Drug: OPC‐8212 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC‐8212 (60 mg/day)
Trial: 6974386
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine against Hemophilus influenzae type b
Trial: 17760597
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNTA) injections at the vermilion border, 1 week before chemabrasion
Trial: 17760597
Drug: Control sides
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control sides (no BoNTA injections)
Trial: 11169020
Drug: High-dose L-5-methyltetrahydrofolate
RxNorm normalized name: L-5-methyltetrahydrofolate
DrugBank: Levomefolic acid (DB11256)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose L-5-methyltetrahydrofolate (MTHF) at 17 mg/day
Trial: 11169020
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) at 15 mg/day
Trial: 11169020
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) at 2.4 mg/day (for RTRs)
Trial: 11169020
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral MTHF (17 mg/day) or FA (15 mg/day) (for HD patients)
Trial: 9701162
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Zn with micronutrients (ZM)
Trial: 9701162
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Zn alone (Z)
Trial: 2812836
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural administration of fentanyl (1 microgram/kg body weight)
Trial: 2812836
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of fentanyl (1 microgram/kg body weight)
Trial: 970905
Drug: Furosemide prophylaxis
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide prophylaxis (20-60 mg) in the short-perfusion group (9 patients)
Trial: 970905
Drug: Furosemide prophylaxis
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide prophylaxis (20-60 mg) in the long-perfusion group (13 patients)
Trial: 22208783
Drug: Piroxicam 10
RxNorm normalized name: piroxicam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 10 mg daily
Trial: 18582572
Drug: Amoxicillin under
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin under fasting conditions
Trial: 18582572
Drug: Amoxicillin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin after intake at the beginning of breakfast
Trial: 18582572
Drug: Amoxicillin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin after breakfast
Trial: 1363664
Drug: Psychosomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosomatic therapy (psychotherapy, relaxation, etc.) alone in group I (9 patients)
Trial: 1363664
Drug: Psychosomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosomatic therapy plus treatment with amineptine and clobazam in group II (9 patients)
Trial: 3910303
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg + Acebutolol 100 mg
Trial: 27485432
Drug: Conventional Treatment
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Treatment (CT) using bulk fill composite resin (Scotchbond™ Universal Adhesive system associated with Filtek Bulk Fill - 3 M/ESPE)
Trial: 27485432
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment (ART) using high viscosity glass ionomer cement (Ketac Molar Easy Mix - 3 M/ESPE)
Trial: 24262503
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (target cyclosporine level 600-700 ng/ml for first 6 months, 450-550 ng/ml for next 18 months)
Trial: 24262503
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (target cyclosporine level 450-550 ng/ml for first 6 months, 300-400 ng/ml for next 18 months)
Trial: 22993341
Drug: Oral azasetron
RxNorm normalized name: alosetron Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral azasetron
Trial: 18806056
Drug: Morphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (1 mg/mL)
Trial: 18806056
Drug: Hydromorphone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.2 mg/mL)
Trial: 12075577
Drug: PEG-OB (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-OB (60 mg weekly for 8 weeks)
Trial: 2537721
Drug: NaHCO3 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 (300 mg.kg‐1 body mass)
Trial: 2537721
Drug: CaCO3 (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaCO3 (placebo, 300 mg.kg‐1 body mass)
Trial: 6455388
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin phosphate
Trial: 6455388
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline hydrochloride
Trial: 26264173
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise during hemodialysis sessions with ankle weights and resistance bands, performed twice a week for 12 weeks
Trial: 20854696
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block injection
Trial: 17986319
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment followed by functional rehabilitation with use of a functional bracing system
Trial: 12032722
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose cyclosporine A (15 mg/kg/day for 2 days, 7.5 mg/kg/day for 2 days, then adjusted to maintain trough blood levels of 100-200 microg/l)
Trial: 12032722
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclosporine A (2 mg/kg/day with no loading dose)
Trial: 2696890
Drug: Ceftazidime i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime i.v. (2 g) in three doses (half an hour before surgery, 8 and 16 hours from the first dose)
Trial: 2696890
Drug: Netilmicin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin (100 mg) plus clindamycin (600 mg i.v.), following the same chronological schedule
Trial: 330290
Drug: Lentizol 50
RxNorm normalized name: Lentizol 50 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentizol 50 mg
Trial: 330290
Drug: Tryptizol 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptizol 75 mg
Trial: 29283612
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment minimal contact control
Trial: 21345470
Drug: Placebo (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham treatment with disconnected magnet therapy device)
Trial: 10831175
Drug: Slow-release lanreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release lanreotide (SR-L) 30 mg
Trial: 9505983
Drug: Methylprednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1 to 80 mg)
Trial: 9505983
Drug: Prednisolone (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (1.25 to 100 mg)
Trial: 9505983
Drug: Prednisolone (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (multiple doses)
Trial: 8415211
Drug: MC pork
RxNorm normalized name: Pork
DrugBank: Pork (DB10561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC pork insulin
Trial: 22796996
Drug: Contrast bath
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast bath therapy
Trial: 22796996
Drug: Cold water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold water immersion and contrast bath therapy
Trial: 9821025
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin (UFH)
Trial: 12574806
Drug: Subcutaneous low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low-molecular-weight heparin (reviparin) twice daily for one week
Trial: 12574806
Drug: Subcutaneous reviparin
RxNorm normalized name: reviparin
DrugBank: Reviparin (DB09259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous reviparin once daily for four weeks
Trial: 12574806
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants for at least 3 months
Trial: 8832013
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of low-dose heparin (100 units/kg/day) from the first day of the preparative regimen to day +30 or until discharge.
Trial: 1848167
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (0.5 and 1.0 ng min-1 kg-1)
Trial: 30367457
Drug: Drug A
RxNorm normalized name: Drug additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug A at the optimal phase I‐II dose
Trial: 30367457
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment C
Trial: 29247172
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (60 mg iron as ferrous fumarate daily)
Trial: 17322539
Drug: pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemetrexed 500 mg/m(2)
Trial: 17322539
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m(2)
Trial: 17322539
Drug: first-line therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: first-line therapy types (gemcitabine + platinum, taxane + platinum, other therapies)
Trial: 15803358
Drug: Clodronate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate treatment
Trial: 12225716
Drug: Diltiazem (Adizem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (Adizem XL) 300 mg once daily
Trial: 12225716
Drug: Amlodipine/atenolol during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/atenolol during drug-free interval
Trial: 10212715
Drug: Alfentanil 5
RxNorm normalized name: alfentanil 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 5 micrograms.kg‐1 and propofol 2.5 mg.kg‐1 (Group A5)
Trial: 10212715
Drug: Alfentanil 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 10 micrograms.kg‐1 and propofol 2.5 mg.kg‐1 (Group A10)
Trial: 10212715
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg.kg‐1 only (Group P)
Trial: 7600753
Drug: Structured teaching
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured teaching and treatment programme
Trial: 1516498
Drug: Gemfibrozil treatment
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil treatment (n = 59)
Trial: 6337667
Drug: Emepronium bromide
RxNorm normalized name: emepronium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emepronium bromide 200 mg qid
Trial: 6337667
Drug: Flavoxate chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavoxate chloride 200 mg qid
Trial: 29735474
Drug: Multicomponent technology‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent technology‐based intervention targeting adherence to daily controller medication (2 sessions of computer‐delivered motivational interviewing and individualized text messaging)
Trial: 24289574
Drug: Basant polyherbal
RxNorm normalized name: Bavisant
DrugBank: Bavisant (DB12299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basant polyherbal vaginal cream
Trial: 24289574
Drug: Curcumin vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin vaginal capsules
Trial: 24289574
Drug: Placebo vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal cream
Trial: 24289574
Drug: Placebo vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal capsules
Trial: 21986570
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of calcium L-threonate (675, 2025, or 4050 mg)
Trial: 21986570
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of calcium L-threonate (2025 mg twice daily for 4 days)
Trial: 21986570
Drug: Cumulative urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative urinary excretion of L-threonate
Trial: 19065098
Drug: Evidence-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based intervention for dementia caregivers, details on dosage and duration not available.
Trial: 19065098
Drug: Volunteer program,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteer program, details on dosage and duration not available.
Trial: 11558843
Drug: Oral slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral slow-release isosorbide dinitrate (ISDN) 20 mg three times a day
Trial: 3972221
Drug: Ileal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ileal infusion of Intralipid
Trial: 30803843
Drug: Inactivated enterovirus
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated enterovirus A71 vaccine, administered in two doses with a 28-day or 56-day interval, booster dose at one year for participants aged two months to <two years
Trial: 30803843
Drug: Inactivated enterovirus
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated enterovirus A71 vaccine
Trial: 29989868
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day of chelated zinc gluconate for one month
Trial: 22805391
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sublingual isosorbide dinitrate (ISDN)
Trial: 20824151
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Pravastatin and Fenofibrate) from weeks 12-48